News
Secukinumab brings high PASI 75 results in 6- to 17-year-olds with psoriasis
The week-24 PASI 75 rate was 95% in a phase 2 study.
News
Enzymatic injections show durable improvement in buttock cellulite
Expert says success with collagenase clostridium histolyticum–aaes injections will be all about managing expectations.
News
Bimekizumab superior to adalimumab in head-to-head psoriasis study
The response to bimekizumab was notably fast.
News
Hedgehog inhibitor alternative dosing advantageous for BCC
The goal of step-down therapy is lifelong tolerability.
News
Coffee could be the secret weapon against NAFLD
Two or more cups daily slashes risk of hepatic cirrhosis and hepatocellular carcinoma.
News
AI system beats endoscopists for detecting early neoplasia in Barrett’s
“I think this will be a really helpful addition, the equivalent of a second endoscopist raising a yellow flag to take a closer look at a...
News
Treatment paradigm for chronic HBV in flux
Some patients achieve functional cure after treatment withdrawal, while others face flares or other challenges.
News
Oral sarecycline promising for papulopustular rosacea
“Always aim for clear skin.”
News
National Psoriasis Foundation recommends some stop methotrexate for 2 weeks after J&J vaccine
The rationale is to optimize the antibody response to the killed-adenovirus COVID-19 vaccine.
News
AI system beats endoscopists for detecting early neoplasia in Barrett’s
“I think this will be a really helpful addition, the equivalent of a second endoscopist raising a yellow flag to take a closer look at a...
News
Experts highlight recent breakthroughs in psoriatic arthritis
Signal of possible gender disparity in PsA response to biologics sparks questions.
News
Will psoriasis patients embrace proactive topical therapy?
Results of year-long PSO-LONG trial show superior efficacy, compared with conventional reactive management.
News
Baricitinib hits mark for severe alopecia areata
Clinically meaningful hair regrowth occurred in the BRAVE-AA1 trial despite 16-year disease duration.
News
Ruxolitinib cream for atopic dermatitis is in regulatory home stretch
Topical JAK inhibitor displayed dual mechanisms of benefit in pivotal trials.